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Nucleotide excision repair (NER) removes DNA
lesions resulting from exposure to UV irradiation
or chemical agents such as platinum-based drugs
used as anticancer molecules. Pharmacological
inhibition of NER is expected to enhance chemosen-
sitivity but nontoxic NER inhibitors are rare. Using a
drug repositioning approach, we identify spironolac-
tone (SP), an antagonist of aldosterone, as a potent
NER inhibitor. We found that SP promotes a rapid
and reversible degradation of XPB, a subunit of
transcription/repair factor TFIIH. Such degradation
depends both on ubiquitin-activating enzyme and
on the 26S proteasome. Supplementation of extracts
from SP-treated cells with purified TFIIH restored
TFIIH-dependent repair and transcription activities
in vitro, demonstrating the specific impact of SP
on two fundamental functions of TFIIH. Finally, SP
potentiated the cytotoxicity of platinum derivatives
toward tumor cells, making it a potential therapeutic
and research tool.
INTRODUCTION
One of the most versatile mammalian repair pathways is nucleo-
tide excision repair (NER), in which two distinct modes of
damage recognition are operating through the sequential
accumulation of NER factors at the damage site (de Boer and
Hoeijmakers, 2000). Within transcription-coupled repair (TCR),
the removal of lesions located on the transcribed strand of
a gene is rapid owing to their detection by the elongating
transcription machinery (Fousteri and Mullenders, 2008). The
XPC-hHR23B complex locates injuries in the nontranscribed
sequences to initiate the slower process of global genome repair
(GGR) (Sugasawa et al., 1998). Both subpathways converge
subsequently into a common process through the recruitment
of the multiprotein complex TFIIH. This transcription/repair
factor contains several enzymatic activities including helicases
(XPB and XPD) and a kinase (cdk7) (Compe and Egly, 2012).398 Chemistry & Biology 21, 398–407, March 20, 2014 ª2014 ElsevieHelicases allow recruitment of the complex and unwinding of
the DNA around the lesion thereby providing a three-dimensional
structure able to recruit XPA and RPA (Oksenych et al., 2009).
The edges of the resulting DNA bubble are recognized by XPG
and ERCC1-XPF, two junction-specific endonucleases with
opposite single-strand polarities that generate 30 and 50 single
DNA incisions relative to the damage, respectively (O’Donovan
et al., 1994; Sijbers et al., 1996). This dual DNA incision leads
to the excision of a 24–32-mer damaged oligonucleotide and
to gap-filling DNA resynthesis (Ogi et al., 2010).
DNA lesions that are removed by NER are chemically and
structurally diverse, being caused by a wide variety of chemical
agents and UV. Among these lesions, those derived from cell
exposure to cisplatin and its derivative have attracted much
attention due to their widespread use in cancer chemotherapy.
Cisplatin, as well as its derivatives (carboplatin, oxaliplatin), is
now largely employed for the treatment of a wide range of solid
tumors, including testicular, bladder, ovarian, colorectal, lung,
and head and neck cancers (Galanski, 2006).
Platinum-based compounds exert their antineoplastic effect
through direct binding to DNA resulting in saturation of several
DNA repair mechanisms, including NER. Consequently, plat-
inum blocks fundamental cellular processes such as transcrip-
tion and replication ultimately resulting in apoptotic cell death.
Because platinum derivatives constitute the major therapeutic
option in many clinical settings, the development of chemo-
sensitization strategies constitutes a goal with important
clinical implications. Indeed, inhibition of DNA repair pathways
such as NER may increase the efficiency of current chemo-
therapeutic regimes, thereby minimizing resistance and ulti-
mately decreasing the possibility of the negative side effects
(Kelland, 2007). However, DNA repair inhibitors are generally
toxic in the own right, whereas siRNA-directed strategies to
knock down proteins have not proven readily applicable in a
clinical setting (Burnett and Rossi, 2012). Hence, we aimed
at identifying potent, nontoxic, and specific drug candidates
able to inhibit NER, thereby potentially improving existing
cancer therapies (Barakat et al., 2012). We established a
cell-based screening assay and applied a chemical library to
this screen. Among the 1,200 molecules tested, spironolactone
(17-hydroxy-7a-mercapto-3-oxo-17a-pregn-4-ene-21-carboxylic
acid g-lactone acetate) (SP) was selected owing to its capacity
to induce a dramatic decrease in NER activity that wasr Ltd All rights reserved
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Figure 1. SP Inhibits the Repair of UV-Induced DNA Damage
(A) Schematic representation of the protocol that was used for the identification of NER inhibitors. Following 12 hr incubation with the chemical library in 96-well
plates, cells were UVC irradiated (60 J/m2), postincubated for 3 hr, and fixed. Subsequently (6-4)PP lesions were labeled using an anti-(6-4)PP antibody and
detected by high throughput microscopy (HTM).
(B) The protocol presented in (A) was validated using shCTL and shXPA HeLa cells. The levels of remaining (6-4)PP lesions was determined using HTM. One
hundred percent corresponds to the (6-4)PP signal measured just after UV irradiation.
(C) Results of the screening performed with the 1,200 small molecules from the Prestwick library tested at 10 mM following the protocol described in (A). The
vertical axis represents the percent of (6-4)PP lesions relative to the level measured right after irradiation that is set to 100% in all experiments.
(D) (6-4)PP repair inhibitory activity of different SP concentrations as determined by HTM. Antazoline (AN) did not induce any (6-4)PP repair inhibitory activity in
our screening and thus was used as negative control. The vertical axis represents the percent of (6-4)PP lesions relative to the level measured just after irradiation
that is set to 100% in all experiments. The values represent the averages (±SD) from three independent experiments.
(E) Structure of Budesonide, Cortisone, Diflorasone, and Eplerenone, four compounds structurally close to SP (shown at the center of the figure).
(F) The relative NER inhibitory activity of Budesonide (1), Cortisone (2), Diflorasone (3), and Eplerenone (4) was determined and compared to SP (5) following
the protocol described in (A). The vertical axis represents the percent of (6-4)PP lesions relative to the level measured just after irradiation that is set to 100% in all
experiments. The values represent averages (±SD) from three independent experiments.
See also Figure S1.
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DNA Repair Inhibitor Targets XPB Helicaseassociated with a rapid and reversible degradation of the
XPB helicase subunit of TFIIH depending both on ubiquitin-
activating enzyme and on proteasome. Furthermore, we have
shown that a combination of SP and platinum derivatives
produced significant increases in cytotoxicity toward human
colon and ovarian carcinoma cells, pointing to the reposition-
ing of this small nontoxic molecule as an adjuvant in plat-
inum-based chemotherapy.Chemistry & Biology 21, 3RESULTS
SP Inhibits the Repair of UV-Induced DNA Lesions
To set up a screening for NER inhibitors, we optimized an assay
detecting UV-induced DNA damages in a 96-well plate and
automated the quantification of the nuclear signal for (6-4)PP
lesions, a major UV-induced lesion (de Laat et al., 1999), through
high-throughput microscopy (HTM) (Figure 1A). During the98–407, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 399
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Figure 2. SP Increases the Sensitivity to
UVC and Cisplatin Treatment
(A and B) Quantitative UV (A) or cisplatin (B) sur-
vival analysis of HeLa cells treated with DMSO or
SP (10 mM). Results are expressed as percent of
cell survival relative to the nontreated controls
that is set to 100%. The values represent averages
(±SD) from three independent experiments;
p value is indicated (**p < 0.01; ***p < 0.001).
(C) Cytotoxic activity of SP(10 mM) or cisplatin
(2.5 mM) in HeLa cells treated 24 hr with the indi-
cated compound and stained with 7-AAD before
flow cytometry analysis. Results are expressed as
percent of dead cells (positive for 7-AAD staining)
in the total population. The values represent
averages (±SD) from three independent experi-
ments; p value is indicated.
(D) Upper panel: increasing amount (1 mg, 3 mg,
and 6 mg) of nuclear extracts from DMSO
(NEDMSO)-treated or SP (NESP)-treated HeLa cells
were analyzed for dual incision. NEs were incu-
bated with cis-platinum mono-damaged plasmid
(Riedl et al., 2003). Incision products are indicated
as radiolabeled 27 nt to 34 nt products. Several
incisions products are observed that depend on
the cutting site of XPG that varies from two to three
nucleotides. As control, a reconstituted system
(Rec) with recombinant proteins was used (Riedl
et al., 2003). Lower panel: similar amount of NE as
tested above was analyzed by western blotting
with an anti-TBP antibody.
(E) DMSO-treated or SP-treated HeLa cells were
incubated in the presence (+) or absence () of
100 ng/ml NCS for 30min. Cells were then cultured
without NCS and harvested at 6 or 24 hr. Cells
were lysed and analyzed by western blotting with
anti-gH2AX or anti-TBP antibodies. When indi-
cated, cells were treated with DNA-PK inhibitor
NU7026 during the recovery time.
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them with UVC (60J/m2) and postincubated them for 3 hr in
drug-free media before processing for (6-4)PP HTM immunoflu-
orescence, using anti-(6-4)PP antibody (Mori et al., 1991). As
proof of principle, use of HeLa cells knocked down for the NER
factor XPA (Le May et al., 2010) was associated with 70% resid-
ual (6-4)PP lesions 3 hr postirradiation, in marked contrast to the
shRNA control cells that displayed 10% residual (6-4)PP signal
(Figure 1B).
Prestwick Chemical Library (http://www.prestwickchemical.
com/index.php?pa=26) containing 1,200 small molecules was
then used at a 10 mM single point concentration. More than
90% of the chemicals had no effect on NER with a (6-4)PP signal
<20% of the initial signal measured just after UV irradiation (Fig-
ure 1C and Figure S1 available online). The compounds that
had resulted in a (6-4)PP signal higher than 80% were studied.
Six of these compounds were excluded because they showed
a high cellular toxicity following the pre-irradiation incubation,
which may explain the NER inhibition. We also excluded
Merbromin as a false positive because it has a major excitation
peak at 498 nm, the wavelength used in our screening. Finally,
only the SP, an aldosterone antagonist that binds to the
mineralocorticoid receptors, was retained as a potential NER
inhibitor candidate. SP was tested at different concentrations400 Chemistry & Biology 21, 398–407, March 20, 2014 ª2014 Elsevieand showed almost complete inhibitory activity at 1 and 10 mM
and a partial response (40% inhibition) at submicromolar con-
centration (Figure 1D).
In the chemical library, some compounds were structurally
related to SP (Figure 1E). We tested several of these chemicals
individually and observed no potent inhibition of NER (Figure 1F).
Eplerenone (Figure 1E) is a SP derivative designed to enhance
the selective binding to the mineralocorticoid receptor (de Gas-
paro et al., 1987). However, Eplerenone did not significantly
inhibit NER in our assay (Figure 1F). We concluded from these
experiments that the effect of SP in preventing the removal of
DNA lesions by NER is an additional and highly specific function
of this molecule, independent from its aldosterone antagonist
function. We therefore focused on this compound for the subse-
quent analyses.
SP Increases Cell Sensitivity to UV and Cisplatin
Treatment
A hallmark of NER-deficient cells is their sensitivity to UV- or
cisplatin-induced DNA lesions (Furuta et al., 2002; Gillet and
Scha¨rer, 2006). In a survival assay, SP-treated cells were more
sensitive to UVC irradiation or cisplatin treatment, compared
to vehicle (DMSO)-treated control cells (Figures 2A and 2B,
respectively). Furthermore, viability values of cells treated withr Ltd All rights reserved
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cells showed no significant cytotoxic activity of this compound
following 24 hr incubation (Figure 2C).
We then prepared nuclear extracts (NE) from HeLa cells
treated with SP (10 mM) for 2 hr and tested them in a dual incision
of a single 1,3-intrastrand d(GpTpG) cisplatin-DNA crosslink
in vitro (Coin et al., 2006). NEs prepared from SP-treated cells
were highly deficient in dual incision assay (Figure 2D), indicating
that SP affects one of the basal steps of NER. Finally, we
analyzed whether the inhibition induced by SP was restricted
to NER or included other DNA repair pathways. For this purpose,
we estimated the rate of double-strand DNA break (DSB) repair
by analyzing the persistence of phosphorylated histone H2AX
(gH2AX) taking place after treatment with the DSB-inducer neo-
carzinostatin (NCS). In unsynchronized cells, the DSB repair rate
in SP-treated cells was not reduced in clear contrast to the
persistence of phospho-H2AX induced by the treatment with
the DNA-PK inhibitor NU7026 (Figure 2E). These findings sug-
gest that SP selectively inhibits NER over DSB repair.
SP Downregulates XPB
The above results indicate that SP hinders a crucial step of the
NER reaction that occurs by sequential assembly of repair fac-
tors at the site of DNA damage (Volker et al., 2001). Therefore,
we examined the distribution of NER factors 15 min after UV
irradiation (100 J/m2) using HeLa cells covered with isopore pol-
ycarbonate filters with 5 mm diameter pores (Volker et al., 2001).
In control cells, immunostaining against the damage recognition
factor XPC showed that it was located in discrete local spots of
the nucleus corresponding to irradiated areas (Figure 3A, panels
a, e, and i). In these cells, p62 (a subunit of TFIIH), XPA, and XPF
colocalized with the XPC spots, indicating that they were effi-
ciently recruited to the damaged sites (Figure 3A, panels c, g,
and k). Surprisingly, while XPC continued to accumulate effi-
ciently on UV-irradiated spots of the SP-treated cells (Figure 3A,
panels b, f, and j), p62, XPA, and XPF did not (Figure 3A, panels
d, h, and i).
We then initiated a systematic analysis of the relative amounts
of NER factors in nuclear extracts obtained from SP-treated
cells lysed at different time points. While the amounts of the
NER factors XPC, XPA, RPA, XPG, and XPF remained un-
changed along the time course, we noticed a rapid decrease
of the concentration of XPB, the biggest TFIIH subunit, after
2 hr treatment with SP (Figure 3B). TFIIH is a ten-subunit factor
(Compe and Egly, 2012): all core subunits that we tested (p62,
p52, p44, or TTDA) were reduced by 6 hr after SP treatment
compared to DMSO vehicle control (Figure 3B). However, the
downregulation of these subunits clearly took place at a slower
rate compared to XPB (Figure S2A). Using a shorter time
course, we determined the half-life of XPB to be 70 min
(Figure S2B).
The results above suggest that the SP-induced NER defi-
ciency is due to a defect in TFIIH. To test this hypothesis, we sup-
plemented NESP with highly purified TFIIH (Coin et al., 1998)
(Figure S2C) in a NER assay and observed a clear recovery of
dual incision (Figure 3C, compare lanes 7–9 to 10–12). In a
normal situation, TFIIH is not a limiting factor because its addition
to NEDMSO did not increase DNA repair (Figure 3C, compare
lanes 1–3 to 4–6).Chemistry & Biology 21, 3We also analyzed the amount of endogenous XPB directly
in vivo by immunofluorescence. The intensity of the nuclear
staining of XPB was strongly reduced after 2 hr treatment with
SP (Figures 3D, panels b–d, and S2D). In contrast, immunostain-
ing of the same cells with anti-XPC antibody did not reveal sig-
nificant differences (Figures 3D, panels a–c, and S2D). Using
live cell imaging, we also monitored the decrease in the nuclear
concentration of exogenous XPB by time-lapse microscopy
following SP treatment of HeLa cells transfected with XPB-
GFP (Oksenych et al., 2009). The homogenous nuclear XPB
signal progressively decreased within the time frame of the SP
treatment (Figure 3E; Movie S1), without any modification of
XPB cellular localization (Movie S1). In total agreement with the
data on endogenous XPB (Figure S2B), we estimated the half-
life of exogenous XPB to be 70 min in the presence of SP.
These results indicate that SP induces a rapid decrease of the
XPB concentration in the nucleus without cellular relocalization
of the protein.
SP Induced Ubiquitin-Activating Enzyme- and
Proteasome-Dependent Degradation of XPB
We next investigated the mechanism of SP-induced XPB
downregulation. Two hour treatment with SP or DMSO was not
associated with any detectable differences in the levels of XPB
mRNA (Figure 4A) indicating a direct effect of SP at the protein
level. Indeed, addition of the proteasome inhibitor MG-132
during SP treatment preserved XPB protein levels (Figure 4B).
We next used PYR-41, a small molecule chemical inhibitor of
ubiquitin-activating enzymes (Yang et al., 2007). HeLa cells
pretreated with PYR-41 did not show any decrease of XPB
following incubation with SP (Figure 4C). Finally, XPB interacts
with Sug1, a component of the 26S proteasome (Weeda et al.,
1997). Accordingly, siRNA-mediated knock down of Sug1
partially restored XPB protein level in SP-treated cells (Figures
4C and S2E). Together, these findings suggest a critical role
for ubiquitin-activating enzymes and the proteasome in the
downregulation of XPB induced by SP.
SP-Induced XPB Degradation Impairs Transcription
Besides its role in DNA repair, TFIIH is also a basal transcription
factor involved in the hormone-dependent transcriptional
response (Compe and Egly, 2012). As a consequence, the effect
of SP on gene expression was studied in HeLa cells by moni-
toring the transcription of Cyp26 and RARb2, two retinoic acid
(t-RA)-responsive genes (Le May et al., 2012). We observed
that 2 hr of exposure to SP (10 mM) before incubation with t-RA
over 6 hr resulted in dose-dependent inhibition of Cyp26 and
RARb2 gene expression (Figures 5A and 5B). In addition, in an
in vitro transcription assay (Gerard et al., 1991), we noticed a
reduced transcriptional activity of the NESP that can be restored
following the addition of purified TFIIH (Figure 5C, compare
lanes 7–9 with 10–12). These data demonstrated that the SP-
induced degradation of XPB impairs both basal and activated
mRNA transcription.
Reversion of SP-Induced Degradation of XPB
We next tested whether the SP-induced degradation of XPBwas
reversible. Following treatment of HeLa cells with SP (10 mM)
for 4 hr, the drug was removed and fresh medium was added98–407, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 401
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Figure 3. SP-Induced NER Deficiency Is due to the Downregulation of TFIIH
(A) Following incubation with DMSO or SP (10 mM) for 2 hr, HeLa cells were locally UV-irradiated (100 J/m2), fixed after 15 min, and costained with antibodies to
XPC (a, b, e, f, i, and j) and to either TFIIH(p62) (c and d), XPA (g and h), or XPF (k and l). Arrows indicate locally irradiated areas.
(B) HeLa cells were incubated with DMSO or SP (10 mM) for the indicated time before lysis. Extracts from DMSO-treated or SP-treated cells were resolved by
SDS-PAGE and subsequently analyzed by immunoblotting. The different proteins are indicated and black arrows point to the corresponding bands. CTL, control.
(C) HeLa cells were incubated with DMSO or SP (10 mM) for 2 hr. Increasing amounts (1 mg, 3 mg, and 6 mg) of nuclear extracts fromDMSO (NEDMSO)-treated or SP
(NESP)-treated HeLa cells were analyzed for dual incision as described in Figure 2C.When indicated, purified TFIIH (100 ng) fromHeLawas added. Optical density
was determined using a Typhoon PhosphorImager 8600 and expressed as relative activity (RA).
(D) HeLa cells were treated with DMSO or SP (10 mM) for 2 hr, fixed and incubated with anti-XPC (a–c) and anti-XPB antibodies (b–d).
(E) HeLa cells were transfected with XPB-GFP and treated with either DMSO or SP (10 mM). Fluorescence was determined by live imaging every 12 min during
120 min and plotted on the graph. The values are indicated relative to the expression level of XPB-GFP before treatment that is set to 100. Values represent
averages (±SD) from three independent experiments.
See also Figure S2 and Movie S1.
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DNA Repair Inhibitor Targets XPB Helicasebefore cells were lysed at different recovery time points. We
observed a progressive recovery of XPB protein level along the
time course of the recovery time (Figure 6A), which was pre-
vented by addition of cycloheximide (CHX), an inhibitor of the
de novo protein synthesis (Figure 6B, lanes 3 and 6). Together402 Chemistry & Biology 21, 398–407, March 20, 2014 ª2014 Elseviewith the restoration of the XPB protein levels, we observed a
recovery of (6-4)PP removal that reached the levels of the
DMSO-treated control cells, 6 hr after the removal of SP (Fig-
ure 6C). These observations indicate that SP-induced degrada-
tion of XPB is rapidly reversible.r Ltd All rights reserved
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Figure 4. SP Induces Ubiquitin-Activating Enzymes and Protea-
some-Dependent Degradation of XPB
(A) HeLa cells were treated with DMSO or SP (10 mM) for 2 hr. Total RNA was
extracted and XPB mRNA was quantified by RT-qPCR. Values are normalized
relative to GAPDH expression. Values represent averages (±SD) from three
independent experiments.
(B) HeLa cells were incubated in the presence (+) or absence () of the pro-
teasome inhibitor MG132 (10 mM) for 1 hr before addition of DMSO or SP
(10 mM) for 4 hr. Cells were lysed and the extracts were resolved by SDS-PAGE
and analyzed by immunoblotting for XPB or TBP.
(C) HeLa cells were incubated in the presence (+) or absence () of the ubiq-
uitin-activating enzyme inhibitor PYR-41 (35 mM) for 2 hr before addition of
DMSO or SP (10 mM) for 4 hr. Cells were lysed and the extracts were resolved
by SDS-PAGE and analyzed by immunoblotting for XPB or TBP.
(D) HeLa cells were transfected with Sug1-pool siRNA or Control (CTL) smart-
pool siRNA (Dharmacon) for 36 hr following incubation with DMSO or SP
(10 mM) for 4 hr. Cells were lysed and extracts were resolved by SDS-PAGE
and analyzed by immunoblotting. The signals were quantified using Genetool
(Syngene) and indicated below the immunoblot.
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Chemistry & Biology 21, 3SP Chemo-Sensitizes Human Cancer Cells to Platinum
Derivatives
To determine the influence of SP on the sensitivity of cancer
cells to platinum-based compounds, we examined the cytotoxic
effect of two platinum-derivatives, cisplatin and oxaliplatin,
toward human cancer cells. In the absence of SP, IC50 values
of cisplatin and oxaliplatin toward A2780 ovarian and HCT-116
colon carcinoma cells were determined to be 2.8 and 1.2 mM,
respectively. Cotreatment with SP significantly decreased the
IC50 values of cisplatin and oxaliplatin to 0.9 and 0.7 mM, respec-
tively (Figures 7A and 7B). Together with an increase in the
platinum-induced cytotoxicity, SP induced XPB degradation in
these cells (Figure 7C). Taken together, our data indicate that
the presence of SP increases the sensitivity of different types
of human cancer cells to platinum-based anticancer agents.
DISCUSSION
In our study, we show that SP induced the degradation of the
XPB subunit of TFIIH, which leads to an impairment of the NER
pathway. Platinum-based agents overwhelm DNA repair mech-
anisms involved in their removal such as the NER pathway.
Consequently, the platinum-derived lesions impair various
DNA-associated processes like replication and transcription
leading to apoptosis of a large fraction of tumor cells. Although
the initial response to platinum is high, there are several limita-
tions to the use of platinum-based compounds in cancer therapy
including the toxic side effects as well as development of
resistance (Ko¨berle et al., 2010). NER is considered to be a vital
target to improve platinum-based cancer therapy and reduce the
resistance (Barakat et al., 2012). Consequently, discovery of
potent, nontoxic DNA repair inhibitors could be an important
step in modern cancer therapy aimed at improving existing
treatments. With this paradigm in mind, we decided to follow a
drug repositioning approach and search for NER inhibitors in
the Prestwick Chemical Library that contain a limited number
of highly diverse drug molecules for which bioavailability and
toxicity studies have already been performed. This characteristic
was a priority for us because the cytotoxicity of many DNA
repair inhibitors such as Wortmannin or caffeine precludes their
clinical use.
Using a functional assay measuring the removal of the (6-4)PP
lesions by HTM, we identified in a drug repositioning approach,
SP as a potent inhibitor of NER. UV irradiation was chosen
instead of platinum for technical reasons but additional experi-
ments performed in vitro and ex vivo demonstrated that similar
inhibition of platinum-derived lesions was observed with SP
(see Figure 2). Strikingly, none of the structurally related analogs
of SP present in the Prestwick library showed potent NER
inhibition indicating that a strict conservation of the structure of
SP is required to obtain NER inhibition. This was further
confirmed by the use of eplerenone, an aldosterone antagonist
that is as derivative of SP, which did not show any NER inhibi-
tion activity. Because the antihypertensive action of eplerenone
and SP includes their binding to the mineralocorticoid receptors,
we conclude that SP impairs NER by a different pathway, unre-
lated to its function as an aldosterone antagonist. In our assay,
SP was used at 10 mM, a concentration that is widely used for
potent inhibitors of ATM or DNA-PKcs tested in cellular assays98–407, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 403
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Figure 5. SP-Induced Degradation of TFIIH
Impairs Transcription
(A and B)mRNA levels forCyp26 (A) andRARb2 (B)
were analyzed in DMSO-treated or SP-treated
cells through the time after the addition of tRA
(1 mM). SP (10 mM) was added to the medium 2 hr
before addition of tRA and kept during the time
course. Expression was represented as the level of
the Cyp26 or RARb2 mRNA relative to GAPDH.
Values represent averages (±SD) from three inde-
pendent experiments.
(C) HeLa cells were incubated with DMSO or SP
(10 mM) for 2 hr. Increasing amounts (1 mg, 3 mg,
and 6 mg) of NEDMSO or NESP were tested in an
in vitro transcription assay using AdML promoter
yielding a 309 nt transcript as indicated. When
indicated, purified TFIIH (100 ng) from HeLa
(Gerard et al., 1991) was added. The signals were
quantified using Genetool (Syngene) and indicated
below the autoradiogram. RA, relative activity.
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at least some NER inhibitory activity even at submicromolar
concentration.
At the molecular level, SP was proposed in an in silico screen-
ing approach to inhibit the interaction between ERCC1 and XPA
(Barakat et al., 2009). However, in our hands, SP targets an even
upstreamNER factor by inducing the potent degradation of XPB,
a subunit of the basal transcription/repair factor TFIIH. Such
degradation seems to depend both on ubiquitin-activating en-
zymes and on the 26S proteasome pathway. In the human ubiq-
uitylation pathway, ubiquitin is adenylated either by UBA1 or
UBA6, the two only ubiquitin-activating enzymes (Jin et al.,
2007). Because the degradation of XPB depends both on ubiqui-
tin-activating enzymes and on the 26S proteasome, we conclude
that XPB undergoes rapid ubiquitylation after SP-treatment that
leads to its quick degradation by the proteasome pathway.
Because TFIIH is also a transcription factor, treatment with SP
induces an inhibition of basal or activated transcription both
in vivo and in vitro. We noted, however, that the basal transcrip-
tion was less hindered compared to DNA repair in vitro in the
presence of SP. This was in agreement with the fact that SP-
treated cells showed very little toxicity and as thus did not
seem to be much affected in their capacity to transcribe genes.
Overall, it appears that a reduction in the amount of TFIIH primary
affects DNA repair before transcription. This observation was
already made in trichotyodystrophy patients who display muta-
tions in subunits of TFIIH leading to a strong reduction of the
amount of TFIIH with a defect in NER but a rather stable
transcription activity in vitro (Vermeulen et al., 2000).
One can then question the specificity of SP on TFIIH. Although
this is a difficult question to tackle, several arguments can be
made on this matter. First, using local UV irradiation, we have
mapped the NER defect induced by SP and identified a defi-
ciency in the recruitment of TFIIH and downstream NER factors
(i.e., XPA or XPF) to the local damaged sites, while the TFIIH-
upstream NER factor XPC was normally recruited. Second,
using an in vitro dual incision assay, we show that addition of404 Chemistry & Biology 21, 398–407, March 20, 2014 ª2014 Elseviepurified TFIIH to NESP was enough to induce a complete recov-
ery of DNA repair. Importantly for the use of SP as a chemosen-
sitizer, its effect on XPB was shown to be reversible because
normal cellular concentrations of TFIIH and NER activity were
quickly restored after SP-removal. SP also impaired the transac-
tivation of t-RA responsive genes upon ligand addition ex vivo
as well as the basal transcription in vitro. Strikingly, addition of
purified TFIIH to SP-treated NE was sufficient to restore tran-
scription. Together, these results pinpoint the high specific
effect of SP on XPB at least in NER and in basal transcription
processes. Thus, SP could serve as an exquisite tool to further
investigate the regulation and function of TFIIH. Indeed, drug-
induced protein degradation offers the possibility of a fine
temporal control over protein levels, compared to RNAi and
biochemical methods that only allow for the constitutive removal
of the protein.
Interestingly, the molecular disruption of TFIIH by SP sensi-
tized tumor cells to platinum-based chemotherapy. The pres-
ence of SP was associated with increased cytotoxicity of
cisplatin and, to a lesser degree, oxaliplatin toward ovarian and
colon carcinoma cells, respectively. This finding may have
important clinical implications, because the combination of SP
and platinum could reduce the risk of relapse by increasing
tumor cell mortality. Alternatively, this might allow a shift to
lower dose of platinum-based compounds that would reduce
the toxic side effects. Such strategy would be particularly attrac-
tive for cancers such as ovarian carcinoma where SP could be
administrated together with cisplatin as an intraperitoneal infu-
sion, where very high drug concentrations can be reached and
where the transcriptional impact of SP on normal cells could
be limited. Ovarian cancer is the ninth most common cancer
among women and ranks fifth in cancer deaths among women,
accounting for more deaths than any other cancer of the female
reproductive system (Coleman et al., 2013). Thus, SP-mediated
inhibition of NER emerges as a possible strategy for enhancing
the efficacy of platinum derivatives although additional work
will be necessary to determine the consequences of ther Ltd All rights reserved
AB
C Figure 6. The SP-Induced Degradation ofXPB Is Reversible
(A) HeLa cells were pretreated with DMSO (lane 1)
or SP (lanes 2–5) (10 mM) for 2 hr. SP was removed
and fresh medium was added. Cells were allowed
to recover for the indicated period of recovery
times (RecTime). Extracts were resolved by SDS-
PAGE and analyzed by immunoblotting for either
XPB or TBP. The signals for XPB and TBP were
quantified using Genetool (Syngene) and plotted
on the graph relative to the signal in DMSO-treated
cells that is set to 1. RA, relative amount.
(B) HeLa cells were pretreated with DMSO (lanes
1–4) or SP (10 mM) (lanes 2, 3, 5, and 6) for 2 hr. SP
was then removed and fresh medium was added
with (lanes 4–6) or without (lanes 1–3) cyclohexi-
mide (CHX, 100 mM). Cells were allowed to recover
for 6 hr before lysing. Extracts were resolved by
SDS-PAGE and analyzed by immunoblotting for
either XPB or TBP.
(C) HeLa cells were treated with DMSO or SP
(10 mM) for 2 hr. SP was removed and fresh
medium was added. Cells were allowed to recover for different recovery times (RT) and subsequently UV-irradiated (60 J/m2), incubated for 3 hr (post-UV), and
fixed. Subsequently (6-4)PP lesions were labeled using anti-(6-4)PP antibodies and detected by HTM. The vertical axis represents the percent of (6-4)PP lesions
relative to the level of (6-4)PP lesions measured just after the irradiation that was set to 100 in all experiments; p value is indicated (**p < 0.01; ***p < 0.001).
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tion activity of normal cells.
Although administration of SP is not harmful in humans, prob-
ably due to its metabolization in the liver (Los et al., 1994), our
study also addressed the consequences of long-term oral
administration of SP. This molecule has been used as a diuretic
and as an antihypertensive drug for more than 30 years. How-
ever, an early study indicated a potential tumorigenic effect
when administrated to rats in the diet (Lumb et al., 1978). Defect
of NER in human causes genetic disorders that predispose
patients to cancers (Lehmann, 2011). Because patients may
receive daily doses of spironolactone for several years, it would
be important to reexamine the chronic effects of SP on patient
tissues following long-term SP treatment.SIGNIFICANCE
In this work, we have used a drug repositioning approach
and drug screening to isolate inhibitors of the nucleotide
excision repair (NER) pathway that deals with bulky DNA le-
sions. NER is a fundamental repair pathway that particularly
repairs platinum-derived lesions used in anticancer chemo-
therapy to kill tumor cells. The rationale behind our idea was
that any potent NER inhibitor could be used as an adjuvant in
platinum-based therapy to increase its efficiency by hinder-
ing cellular mechanisms that naturally reduce its efficacy.
The advantage of drug repositioning is that drugs tested
are usually not cytotoxic, and their application for any given
new therapy may be quicker because these molecules are
already used in the human. Using this approach, we isolated
spironolactone as a potent NER inhibitor. Themechanism of
spironolactone-induced NER inhibition was also investi-
gated, and we found that one NER factor, the XPB helicase
of TFIIH, was specifically degraded a few minutes after
addition of the drug. XPB is recruited to the damaged areaChemistry & Biology 21, 3by XPC and is required for the subsequent recruitment of
XPA, XPG, and ERCC1-XPF. In the presence of spironolac-
tone, XPC is still recruited to the damage but XPA, XPG,
and ERCC1-XPF are not. We also observed that the removal
of spironolactone leads to a rapid recovery of XPB protein
and NER activity showing the reversibility of spironolactone
action. We also demonstrate that cotreatment of various
tumor cells with spironolactone and platinum derivatives
leads to reduced IC50 showing the potentialization of plat-
inum treatment in the presence of our NER inhibitor.
EXPERIMENTAL PROCEDURES
Cell Lines
Parental A2780 and cisplatin-resistant A2780/CP70 ovarian carcinoma cells
were kindly provided by Robert Brown (Imperial College London, UK) while
the HCT-116 colon carcinoma cells were a gift from Bert Vogelstein (John
Hopkins Kimmel Cancer Center, Baltimore, MD). Oxaliplatin-resistant HCT-
116 (HCT-116/oxa) cells were developed in the laboratory of Annette K. Larsen
as described (Petitprez et al., 2013). The nucleotide excision repair capacity
of the four cell lines as determined by unscheduled DNA synthesis following
UVC radiation has been described previously (Soares et al., 2011).
Cell Viability Assays
The HeLa cell line was plated (25,000 cells per well in 6-well Petri dishes),
cultured overnight, and treated with 10 mM spironolactone or 0.1% DMSO
(control cells) for 4 hr before irradiation with various doses of UVC (Philips
TUV lamp, predominantly 254 nm) or exposition to various doses of cisplatin
for 1 hr. Four days later, cells were stained with 0.2% Crystal Violet (Sigma).
After washing with tap water and drying, the stain was solubilized with 1%
SDS and the optical density was measured by 96-well plate reader (595 nm).
All values are averages of at least three independent experiments each done
in duplicate.
MTT Cytotoxicity Assay
Cancer cells were exposed to cisplatin or oxaliplatin in the presence of various
modulators (10 mM) for 120 hr and the cellular viability was determined by the
MTT tetrazolium dye [3-(4,5-dimethyl- thiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay (Sigma) as previously described (Poindessous et al., 2003).98–407, March 20, 2014 ª2014 Elsevier Ltd All rights reserved 405
A B C
Figure 7. SP Sensitizes Human Carcinoma Cells to Platinum Derivatives
(A and B) The MTT assay was used to measure cell viability of either A2780 (A) or HCT-116 (B) human carcinoma cells after treatment with cisplatin or oxaliplatin
(0.1 to 50 mM), respectively, in the presence of AN (10 mM), SP (10 mM), or DMSO. Values represent averages (±SD) from three independent experiments. The
p values (*p < 0.05; **p < 0.01; ***p < 0.001) and IC50 are indicated. One hundred percent corresponds to the amount of cells without any drugs.
(C) A2780 andHCT-116 cells were incubated with DMSO or SP (10 mM) for 4 hr before lysis. Extracts were resolved by SDSPAGE and subsequently analyzed by
immunoblotting for XPB or TBP.
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HeLa cells were treated with DMSO, 10 mM SP, or 2.5 mM cis-diammineplati-
num (II) dichloride (Sigma) for 24 hr, stained with 7-aminoactinomycin D
(7-AAD Viability Dye, Beckman Coulter) according to manufacturer’s instruc-
tions, and analyzed by flow cytometry.
Dual Incision
Dual incision was carried out as described in Riedl et al. (2003). Briefly, dual
incision assay was carried out in 25 ml of incision buffer (45 mM HEPES-
KOH [pH7.8], 5 mM MgCl2, 1 mM DTT, 0.3 mM EDTA, 10% glycerol, 2.5 mg
BSA, and 50 mM KCl) supplemented with 2 mM ATP. Following preincubation
for 10 min at 30C, 30 ng of monodamaged platinum DNA was added and
reactionwas continued for 30min at 30C. The excised fragmentwas detected
on 14% urea-acrylamide after annealing with 9 ng of the complementary oligo-
nucleotide and addition of four radiolabeled dCMPa-P32 (3,000 mCi/mmol) res-
idues by Sequenase V2.1 (USB).
Transactivation Assay
RAR-dependent gene activation was performed as described (Keriel et al.,
2002). Briefly, 13 106 cells were incubated with medium in a 10 cm cell culture
dish for 24 hr. Twelve hours before ligand treatment, cells were incubated with
phenol red-free medium containing 10% charcoal-treated fetal calf serum
(FCS) and 40 mg/ml gentamycin. Cells were treated with 10 mM all-trans reti-
noic acid (tRA).
Run-Off Transcription
Reactionmixtures of 12 ml containing 50 ng of linear AdMLP DNA template and
the indicated amount of HeLa nuclear extract was preincubated for 5 min at
30C in transcription buffer (20 mM HEPES [pH 7.9], 7 mM MgCl2, 55 mM
KCl) and transcription was initiated by the addition of 2 ml nucleotide solution
to final concentrations of 600 mM UTP, ATP, GTP, and 0.6 mM [a-32P] CTP.
Reactions were carried out for 30 min and then stopped by the addition of
0.5 ml of 0.5 M EDTA (pH 8). The resulting RNA transcripts were analyzed on
an 8% denaturing polyacrylamide gel.
Statistical Analysis
The statistical analysis of experimental data was performed using a Student’s
paired t test, and results are presented as mean ± SD; p values are shown
(*p < 0.05; **p < 0.01; ***p < 0.001).
Antibodies
Anti-XPB (1B3), anti-p62 (3C9), anti-p44 (1H5), anti-p52 (1D11), anti-XPA
(1E11), anti-RPA p32 (IE9), anti-Sug1 (1H9 and 1B8), anti-TBP (3G3), and
anti-XPG (1B5) are in-house mouse monoclonal antibodies produced from406 Chemistry & Biology 21, 398–407, March 20, 2014 ª2014 Elsevieascites. Anti-XPF (Ab-5 clone 51) antibody was obtained from Thermo
Fisher Scientific, anti-phospho-Histone H2A.X (Ser139) (clone JBW301) from
Millipore, anti-XPC (A301-122A) from Bethyl; XPB degradation was also
verified using anti-XPB antibody (S-19) from Santa-Cruz Biotechnology.
Anti-6-4PP were from Cosmobio (64M-2).
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